DF
EDIT icon

Dunhill Financial’s Editas Medicine EDIT Stock Holding History

Dunhill Financial’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13K Hold
4,000
– – ﹤0.01% 543
2026
Q1 		$9.88K Hold
4,000
– – ﹤0.01% 538
2025
Q4 		$8.2K Buy
+4,000
New +$11.5K ﹤0.01% 525

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Dunhill Financial's EDIT Position: Q2 2026 in Review

Dunhill Financial held its Editas Medicine (EDIT) position steady in Q2 2026 at 4,000 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #543.

Dunhill Financial first reported a position in EDIT in Q4 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Dunhill Financial held 4,000 shares of Editas Medicine worth $13K as of Q2 2026.
  • Dunhill Financial left its Editas Medicine share count unchanged in Q2 2026.
  • Editas Medicine made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #543 holding.
  • Dunhill Financial first reported a position in Editas Medicine in Q4 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.